Your firm failed to have, for each batch of medical gas, appropriate laboratory determination of satisfactory conformance to final specifications for the medical gas, including the identity and strength of each active ingredient, prior to release (21 CFR 213.165(a)). 1 Your firm is a manufacturer of Oxygen, USP for administration by inhalation, including for use in hospital settings.
Your firm failed to adequately test finished batches of your medical gases for the identity and strength of your active ingredients (Oxygen, USP) before release and distribution, which includes using properly calibrated instruments. For example, while reviewing an investigation into a customer complaint for a medical gas mix-up, our investigator identified that your filling technician reported passing testing results for batches of Oxygen, USP prior to their release without actually performing the required tests. The customer complaint revealed that third-party testing of the Oxygen, USP batches showed the presence of (b)(4) as high as 99% within the containers. A container labeled as medical oxygen administered to a patient despite having a level of 99% (b)(4) (and less than 1% oxygen) represents a catastrophic, immediately life-threatening event from complete oxygen deprivation. Appropriate release testing, which includes strength and identity testing of the active ingredient, must be performed before drug product batch release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that your medical gases conform to appropriate specifications before release. Further, a second person verification (witness) of all critical testing and adequate review of the testing results by the quality unit prior to release of the drug products should be documented to ensure accuracy and accountability.
In your response, you state that you are in the process of developing and implementing comprehensive standard operating procedures (SOPs) with the relocation to your new facility, including procedures for testing and release for distribution. Additionally, you state that you are updating your fill logs to include a second-person verification and plan to record all testing results to enhance the accountability of the testing.
Your response is inadequate because you failed to provide your finished product specifications for Oxygen, USP, procedures for medical gas testing and release, evidence of proper calibration of your testing instruments, or testing results to demonstrate that your firm can manufacture medical gases that meet all quality attributes.
In response to this letter, provide: A list of all test methods and specifications used to analyze each batch of your drug product before making a batch disposition decision, and the associated written procedures.
- A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies.
- Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.